Immunotherapy versus chemotherapy as adjuvant therapy for resected MSI-H/dMMR colorectal cancer: real-world evidence informing precision strategies.

ABSTRACT:

Background​​

Immunotherapy has demonstrated unique advantages in MSI-H/dMMR colorectal cancer (CRC) for its later-line, first-line in metastatic status, and neoadjuvant therapy. However, evidence regarding its value in postoperative adjuvant therapy remains limited.

Methods​​

We retrospectively analyzed 261 stage II/III MSI-H/dMMR CRC patients who underwent radical resection with over 2 years of follow-up. Disease-free survival (DFS) curves were used to compare prognoses under different postoperative strategies, and factors associated with recurrence were investigated.

Results​​

The patients cohort (mean age 55.3, range 19-86 years and male for 56.3%) had a median follow-up of 30 (range 24-45) months. Recurrence occurred in 18 patients (6.9%), with an overall DFS rate

SUBMITTER: Sun H 

PROVIDER: S-EPMC12549702 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature